Key result
Elevated cardiac troponin marks myocardial injury and predicts worse clinical outcomes in COVID-19 patients.
Why the study?
Myocardial injury in COVID-19 patients with elevated cardiac troponin has been observed, but the exact mechanisms and prognostic utility remain unclear.
This review highlights the mechanisms of myocardial injury in COVID-19 and underscores the prognostic utility of cardiac troponin in these patients.
Answers are grounded in this paper and cite their sources.
Myocardial injury mechanisms in COVID-19 with elevated cTn remain unclear; leaves open targeted studies to clarify dominant pathways.
There has been strong evidence of myocardial injury in COVID-19 patients with significantly elevated serum cardiac troponin (cTn). While the exact mechanism of injury is unclear, possible suggested pathological mechanisms of injury are discussed. These include increased susceptibility of the myocardium and endothelium to viral invasion, underlying hyperinflammatory state and subsequent cytokine storm, a hypercoagulable and prothrombotic state, and indirect myocardial injury due to hypoxemia. As a result of these pathological mechanisms in COVID-19 patients, cTn may be elevated largely due to myocarditis, microangiopathy or myocardial infarction. The utility of cTn as a biomarker for measuring myocardial injury in these patients and assessing its ability as a prognostic factor for clinical outcome is also discussed.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2021) conducted a review in COVID-19. Cardiac troponins was evaluated. Elevated cardiac troponin in COVID-19 patients indicates myocardial injury and serves as a prognostic biomarker for clinical outcomes, driven by mechanisms like viral invasion and cytokine storm.
Synapse has enriched 10 related papers. Consider them for comparative context: